KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis.

Ashley L Lennox, Libo Sun, Fei Huang, Melissa Kelly Behrs, Robert Kleiman, Hongqi Xue, Neha Bhise, Ying Wan, Tymara Berry, Faye Feller, Peter N Morcos

Clin Transl Sci 18(2) e70169

PMID39980062
PMCIDPMC11842220
DOI10.1111/cts.70169
发表日期2025-02-20
入排依据:The study is a Phase III randomized trial of imetelstat in myelodysplastic syndromes, but the report is a translational/safety analysis focused on proarrhythmic potential and QTc prolongation. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier curves or hazard ratios. The primary outcome described is the concentration-QTc relationship, which is a safety endpoint.
摘要

摘要

Evaluation of the proarrhythmic potential of imetelstat, a novel oligonucleotide telomerase inhibitor, in nonclinical and clinical studies is presented. In vitro, imetelstat sodium ≤ 750 μg/mL and negative (vehicle) and positive (cisapride) controls were evaluated for hERG channel current inhibition. In vivo, cynomolgus monkeys received a single vehicle control or imetelstat sodium (5 mg/kg [2-h infusion], 10 mg/kg [6-h infusion], or 15 mg/kg [6- or 24-h infusion]); cardiovascular parameters were collected before and after drug administration. A ventricular repolarization substudy of the IMerge phase III study evaluated patients with lower-risk myelodysplastic syndromes administered imetelstat 7.1 mg/kg active dose every 4 weeks; intensive electrocardiograms and pharmacokinetic samples were collected for concentration-QTc and by-time point analyses after a single dose. In vitro, imetelstat did not inhibit the hERG channel (IC50 > 750 μg/mL). In monkeys, imetelstat demonstrated no treatment-related changes in cardiac parameters, including QTc using Fridericia correction (QTcF). In the IMerge QTc substudy, 45 patients received imetelstat (n = 29) or placebo (n = 16). The concentration-QTc relationship was described by a linear mixed-effects model; at the geometric mean maximum plasma concentration (Cmax) for imetelstat 7.1 mg/kg of 89.5 μg/mL, the predicted effect on placebo-corrected change from baseline QTcF was 2.36 ms (90% confidence interval, -3.04 to 7.76), supporting no evidence of QTcF prolongation. By-time point analysis demonstrated no clinically significant effect of imetelstat on QTc. Nonclinical studies demonstrated no proarrhythmic risk at > 140× (in vitro) and > 2.6× (in vivo) imetelstat 7.1 mg/kg Cmax. Clinical evaluations showed no significant effects on QTcF or other electrocardiogram parameters at 7.1 mg/kg. Collectively, this integrated risk assessment supports the low proarrhythmic potential of imetelstat.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。